FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978080134> ?p ?o ?g. }

• W1978080134 endingPage "2120" @default.
• W1978080134 startingPage "2113" @default.
• W1978080134 abstract "Background— Homozygous familial hypercholesterolemia is a rare, serious disorder with a substantial reduction in low-density lipoprotein (LDL) receptor function, severely elevated LDL cholesterol, cardiovascular disease, and often death in childhood. Response to conventional drug therapies is modest. Monoclonal antibodies to proprotein convertase subtilisin/kexin 9 (PCSK9) reduce LDL cholesterol in heterozygous familial hypercholesterolemia. The effect in homozygous familial hypercholesterolemia is unknown and uncertain. We evaluated the efficacy and safety of AMG 145 in an open-label, single-arm, multicenter, dose-scheduling pilot study in patients with homozygous familial hypercholesterolemia. Methods and Results— Eight patients with LDL receptor–negative or –defective homozygous familial hypercholesterolemia on stable drug therapy were treated with subcutaneous 420 mg AMG 145 every 4 weeks for ≥12 weeks, followed by 420 mg AMG 145 every 2 weeks for an additional 12 weeks. All patients completed both treatment periods. Mean change from baseline in LDL cholesterol at week 12 was −16.5% (range, 5.2% to −43.6%; P =0.0781) and −13.9% (range, 39.9% to −43.3%; P =0.1484) with 4- and 2-week dosing, respectively. No reduction was seen in the 2 receptor-negative patients. Over the treatment periods, mean±SD LDL cholesterol reductions in the 6 LDL receptor–defective patients were 19.3±16% and 26.3±20% with 4- and 2-week dosing, respectively ( P =0.0313 for both values), ranging from 4% to 48% with 2-week dosing. No serious side effects were reported. Conclusion— This study demonstrates significant and dose-related LDL cholesterol lowering with a PCSK9 monoclonal antibody in homozygous familial hypercholesterolemia patients with defective LDL receptor activity but no reduction in those who were receptor negative. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifiers: NCT01588496 and NCT01624142." @default.
• W1978080134 created "2016-06-24" @default.
• W1978080134 creator A5020693718 @default.
• W1978080134 creator A5032281288 @default.
• W1978080134 creator A5044425699 @default.
• W1978080134 creator A5049272753 @default.
• W1978080134 creator A5063718631 @default.
• W1978080134 creator A5086317157 @default.
• W1978080134 date "2013-11-05" @default.
• W1978080134 modified "2023-10-13" @default.
• W1978080134 title "Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia" @default.
• W1978080134 cites W1543117447 @default.
• W1978080134 cites W1968949098 @default.
• W1978080134 cites W1989730880 @default.
• W1978080134 cites W2010505181 @default.
• W1978080134 cites W2019757445 @default.
• W1978080134 cites W2026205222 @default.
• W1978080134 cites W2040612932 @default.
• W1978080134 cites W2046141067 @default.
• W1978080134 cites W2046959088 @default.
• W1978080134 cites W2052011436 @default.
• W1978080134 cites W2066398399 @default.
• W1978080134 cites W2079699385 @default.
• W1978080134 cites W2096075279 @default.
• W1978080134 cites W2102238081 @default.
• W1978080134 cites W2103487568 @default.
• W1978080134 cites W2103647780 @default.
• W1978080134 cites W2106285889 @default.
• W1978080134 cites W2108956796 @default.
• W1978080134 cites W2128030263 @default.
• W1978080134 cites W2130480697 @default.
• W1978080134 cites W2131548964 @default.
• W1978080134 cites W2142526970 @default.
• W1978080134 cites W2143741651 @default.
• W1978080134 cites W2157115489 @default.
• W1978080134 cites W2168876694 @default.
• W1978080134 cites W4243500197 @default.
• W1978080134 doi "https://doi.org/10.1161/circulationaha.113.004678" @default.
• W1978080134 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24014831" @default.
• W1978080134 hasPublicationYear "2013" @default.
• W1978080134 type Work @default.
• W1978080134 sameAs 1978080134 @default.
• W1978080134 citedByCount "282" @default.
• W1978080134 countsByYear W19780801342013 @default.
• W1978080134 countsByYear W19780801342014 @default.
• W1978080134 countsByYear W19780801342015 @default.
• W1978080134 countsByYear W19780801342016 @default.
• W1978080134 countsByYear W19780801342017 @default.
• W1978080134 countsByYear W19780801342018 @default.
• W1978080134 countsByYear W19780801342019 @default.
• W1978080134 countsByYear W19780801342020 @default.
• W1978080134 countsByYear W19780801342021 @default.
• W1978080134 countsByYear W19780801342022 @default.
• W1978080134 countsByYear W19780801342023 @default.
• W1978080134 crossrefType "journal-article" @default.
• W1978080134 hasAuthorship W1978080134A5020693718 @default.
• W1978080134 hasAuthorship W1978080134A5032281288 @default.
• W1978080134 hasAuthorship W1978080134A5044425699 @default.
• W1978080134 hasAuthorship W1978080134A5049272753 @default.
• W1978080134 hasAuthorship W1978080134A5063718631 @default.
• W1978080134 hasAuthorship W1978080134A5086317157 @default.
• W1978080134 hasBestOaLocation W19780801341 @default.
• W1978080134 hasConcept C126322002 @default.
• W1978080134 hasConcept C134018914 @default.
• W1978080134 hasConcept C2777288759 @default.
• W1978080134 hasConcept C2778163477 @default.
• W1978080134 hasConcept C2778824825 @default.
• W1978080134 hasConcept C2778849439 @default.
• W1978080134 hasConcept C2779120738 @default.
• W1978080134 hasConcept C2780072125 @default.
• W1978080134 hasConcept C2780948078 @default.
• W1978080134 hasConcept C43554185 @default.
• W1978080134 hasConcept C71924100 @default.
• W1978080134 hasConcept C90924648 @default.
• W1978080134 hasConceptScore W1978080134C126322002 @default.
• W1978080134 hasConceptScore W1978080134C134018914 @default.
• W1978080134 hasConceptScore W1978080134C2777288759 @default.
• W1978080134 hasConceptScore W1978080134C2778163477 @default.
• W1978080134 hasConceptScore W1978080134C2778824825 @default.
• W1978080134 hasConceptScore W1978080134C2778849439 @default.
• W1978080134 hasConceptScore W1978080134C2779120738 @default.
• W1978080134 hasConceptScore W1978080134C2780072125 @default.
• W1978080134 hasConceptScore W1978080134C2780948078 @default.
• W1978080134 hasConceptScore W1978080134C43554185 @default.
• W1978080134 hasConceptScore W1978080134C71924100 @default.
• W1978080134 hasConceptScore W1978080134C90924648 @default.
• W1978080134 hasIssue "19" @default.
• W1978080134 hasLocation W19780801341 @default.
• W1978080134 hasLocation W19780801342 @default.
• W1978080134 hasOpenAccess W1978080134 @default.
• W1978080134 hasPrimaryLocation W19780801341 @default.
• W1978080134 hasRelatedWork W2024110748 @default.
• W1978080134 hasRelatedWork W2029459374 @default.
• W1978080134 hasRelatedWork W2083941082 @default.
• W1978080134 hasRelatedWork W2086942972 @default.
• W1978080134 hasRelatedWork W2099136586 @default.
• W1978080134 hasRelatedWork W2258338427 @default.
• W1978080134 hasRelatedWork W2574261439 @default.

• next